Next Science Limited Stock Performance
| NXSCF Stock | USD 0.06 0.02 28.75% |
On a scale of 0 to 100, Next Science holds a performance score of 4. The company secures a Beta (Market Risk) of 1.9, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Next Science will likely underperform. Please check Next Science's downside variance, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Next Science's current price movements will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Next Science Limited are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental indicators, Next Science reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 19.9 M | |
| Total Cashflows From Investing Activities | -716.8 K |
Next |
Next Science Relative Risk vs. Return Landscape
If you would invest 5.60 in Next Science Limited on September 27, 2025 and sell it today you would earn a total of 0.10 from holding Next Science Limited or generate 1.79% return on investment over 90 days. Next Science Limited is currently producing 0.9129% returns and takes up 14.9031% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Next, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Next Science Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Next Science's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Next Science Limited, and traders can use it to determine the average amount a Next Science's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0613
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NXSCF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Next Science is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Next Science by adding it to a well-diversified portfolio.
Next Science Fundamentals Growth
Next Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Next Science, and Next Science fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Next Pink Sheet performance.
| Return On Equity | -0.77 | |||
| Return On Asset | -0.39 | |||
| Profit Margin | (1.12) % | |||
| Operating Margin | (1.14) % | |||
| Current Valuation | 91.45 M | |||
| Shares Outstanding | 214.79 M | |||
| Price To Book | 7.22 X | |||
| Price To Sales | 9.21 X | |||
| Revenue | 8.95 M | |||
| EBITDA | (8.82 M) | |||
| Cash And Equivalents | 11.06 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 1.34 M | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 0.07 X | |||
| Cash Flow From Operations | (8.26 M) | |||
| Earnings Per Share | (0.05) X | |||
| Total Asset | 13.72 M | |||
About Next Science Performance
By analyzing Next Science's fundamental ratios, stakeholders can gain valuable insights into Next Science's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Next Science has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Next Science has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia. Next Science operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Next Science Limited performance evaluation
Checking the ongoing alerts about Next Science for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Next Science Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Next Science Limited is way too risky over 90 days horizon | |
| Next Science Limited has some characteristics of a very speculative penny stock | |
| Next Science Limited appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 8.95 M. Net Loss for the year was (9.35 M) with profit before overhead, payroll, taxes, and interest of 6.94 M. | |
| Next Science Limited has accumulated about 11.06 M in cash with (8.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. | |
| Roughly 53.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Next Science's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Next Science's stock is overvalued or undervalued compared to its peers.
- Examining Next Science's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Next Science's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Next Science's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Next Science's pink sheet. These opinions can provide insight into Next Science's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Next Pink Sheet analysis
When running Next Science's price analysis, check to measure Next Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Next Science is operating at the current time. Most of Next Science's value examination focuses on studying past and present price action to predict the probability of Next Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Next Science's price. Additionally, you may evaluate how the addition of Next Science to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |